{"id":"https://openalex.org/W4361947372","doi":"https://doi.org/10.1158/1078-0432.c.6530526","title":"Data from A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non\u2013Small Cell Lung Cancer","display_name":"Data from A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non\u2013Small Cell Lung Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361947372","doi":"https://doi.org/10.1158/1078-0432.c.6530526"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6530526","doi":"https://doi.org/10.1158/1078-0432.c.6530526","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6530526","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6530526","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036970226","display_name":"Michael Rahman Shafique","orcid":"https://orcid.org/0000-0003-4232-7629","observed_orcids":["https://orcid.org/0000-0003-4232-7629"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Shafique","raw_affiliation_strings":["Department of Thoracic Oncology, Moffitt Cancer Center and Research Insti-tute, Tampa, Florida"],"raw_orcid":"https://orcid.org/0000-0003-4232-7629","affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, Moffitt Cancer Center and Research Insti-tute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022624265","display_name":"Terrence Lee Fisher","orcid":"https://orcid.org/0000-0001-9326-6606","observed_orcids":["https://orcid.org/0000-0001-9326-6606"]},"institutions":[{"id":"https://openalex.org/I4210141595","display_name":"Vaccinex (United States)","ror":"https://ror.org/047jxj944","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141595"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Terrence L. Fisher","raw_affiliation_strings":["Vaccinex, Inc., Rochester, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vaccinex, Inc., Rochester, New York","institution_ids":["https://openalex.org/I4210141595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001292309","display_name":"Elizabeth E. Evans","orcid":"https://orcid.org/0000-0002-9287-9221","observed_orcids":["https://orcid.org/0000-0002-9287-9221"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210141595","display_name":"Vaccinex (United States)","ror":"https://ror.org/047jxj944","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141595"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Elizabeth E. Evans","raw_affiliation_strings":["Vaccinex, Inc., Rochester, New York","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vaccinex, Inc., Rochester, New York","institution_ids":["https://openalex.org/I4210141595"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001835930","display_name":"John E. Leonard","orcid":"https://orcid.org/0000-0003-2154-750X","observed_orcids":["https://orcid.org/0000-0003-2154-750X"]},"institutions":[{"id":"https://openalex.org/I4210141595","display_name":"Vaccinex (United States)","ror":"https://ror.org/047jxj944","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John E. Leonard","raw_affiliation_strings":["Vaccinex, Inc., Rochester, New York"],"raw_orcid":"https://orcid.org/0000-0003-2154-750X","affiliations":[{"raw_affiliation_string":"Vaccinex, Inc., Rochester, New York","institution_ids":["https://openalex.org/I4210141595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030373204","display_name":"Desa Rae E. Pastore","orcid":"https://orcid.org/0009-0007-7840-8099","observed_orcids":["https://orcid.org/0009-0007-7840-8099"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Desa Rae E. Pastore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114035061","display_name":"Crystal L. Mallow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141595","display_name":"Vaccinex (United States)","ror":"https://ror.org/047jxj944","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Crystal L. Mallow","raw_affiliation_strings":["Vaccinex, Inc., Rochester, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vaccinex, Inc., Rochester, New York","institution_ids":["https://openalex.org/I4210141595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112620955","display_name":"Ernest Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141595","display_name":"Vaccinex (United States)","ror":"https://ror.org/047jxj944","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ernest Smith","raw_affiliation_strings":["Vaccinex, Inc., Rochester, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vaccinex, Inc., Rochester, New York","institution_ids":["https://openalex.org/I4210141595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054475634","display_name":"Vikas Mishra","orcid":"https://orcid.org/0000-0001-7162-5882","observed_orcids":["https://orcid.org/0000-0001-7162-5882"]},"institutions":[{"id":"https://openalex.org/I4210141595","display_name":"Vaccinex (United States)","ror":"https://ror.org/047jxj944","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vikas Mishra","raw_affiliation_strings":["Vaccinex, Inc., Rochester, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vaccinex, Inc., Rochester, New York","institution_ids":["https://openalex.org/I4210141595"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Andreas Schr\u00f6der","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Andreas Schr\u00f6der","raw_affiliation_strings":["Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050974773","display_name":"Kevin M. Chin","orcid":"https://orcid.org/0000-0002-5062-4159","observed_orcids":["https://orcid.org/0000-0002-5062-4159"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin M. Chin","raw_affiliation_strings":["EMD Serono Research & Development, Inc., Billerica, Massachusetts;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research & Development, Inc., Billerica, Massachusetts;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003887338","display_name":"Joseph Thaddeus Beck","orcid":"https://orcid.org/0000-0002-3341-9903","observed_orcids":["https://orcid.org/0000-0002-3341-9903"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210107699","display_name":"Highlands Oncology Group","ror":"https://ror.org/01k1j7593","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210107699"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Joseph T. Beck","raw_affiliation_strings":["Highlands Oncology Group, Fayetteville, Arkansas","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":"https://orcid.org/0000-0002-3341-9903","affiliations":[{"raw_affiliation_string":"Highlands Oncology Group, Fayetteville, Arkansas","institution_ids":["https://openalex.org/I4210107699"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019666128","display_name":"Megan Ann Baumgart","orcid":"https://orcid.org/0000-0002-1122-3934","observed_orcids":["https://orcid.org/0000-0002-1122-3934"]},"institutions":[{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Megan A. Baumgart","raw_affiliation_strings":["University of Rochester, Rochester, New York"],"raw_orcid":"https://orcid.org/0000-0002-1122-3934","affiliations":[{"raw_affiliation_string":"University of Rochester, Rochester, New York","institution_ids":["https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068824818","display_name":"Ramaswamy Govindan","orcid":"https://orcid.org/0000-0002-6964-9612","observed_orcids":["https://orcid.org/0000-0002-6964-9612"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Ramaswamy Govindan","raw_affiliation_strings":["Washington University School of Medicine, St. Louis, Missouri","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine, St. Louis, Missouri","institution_ids":["https://openalex.org/I204465549"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111512954","display_name":"Nashat Y. Gabrail","orcid":"https://orcid.org/0009-0007-3885-3622","observed_orcids":["https://orcid.org/0009-0007-3885-3622"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Nashat Y. Gabrail","raw_affiliation_strings":["Gabrail Cancer Center, Canton, Ohio","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gabrail Cancer Center, Canton, Ohio","institution_ids":["https://openalex.org/I4210100169"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044613951","display_name":"Alexander I. Spira","orcid":"https://orcid.org/0000-0003-1303-0447","observed_orcids":["https://orcid.org/0000-0003-1303-0447"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210122908","display_name":"Virginia Cancer Specialists","ror":"https://ror.org/03tbabt10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210122908"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Alexander I. Spira","raw_affiliation_strings":["Virginia Cancer Specialists and US Oncology Research, The Woodlands, Texas","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Cancer Specialists and US Oncology Research, The Woodlands, Texas","institution_ids":["https://openalex.org/I4210122908"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020651485","display_name":"Nagashree Seetharamu","orcid":"https://orcid.org/0000-0002-3282-7622","observed_orcids":["https://orcid.org/0000-0002-3282-7622"]},"institutions":[{"id":"https://openalex.org/I1302444339","display_name":"Northwell Health","ror":"https://ror.org/02bxt4m23","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339"]},{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Nagashree Seetharamu","raw_affiliation_strings":["Northwell Health Cancer Institute, Lake Success, New York","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":"https://orcid.org/0000-0002-3282-7622","affiliations":[{"raw_affiliation_string":"Northwell Health Cancer Institute, Lake Success, New York","institution_ids":["https://openalex.org/I1302444339"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034847496","display_name":"Yanyan Lou","orcid":"https://orcid.org/0000-0001-6207-9461","observed_orcids":["https://orcid.org/0000-0001-6207-9461"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Yanyan Lou","raw_affiliation_strings":["Department of Hematology and Oncology, Jackson-ville, Florida","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, Jackson-ville, Florida","institution_ids":[]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071440718","display_name":"Aaron Scott Mansfield","orcid":"https://orcid.org/0000-0002-9483-6903","observed_orcids":["https://orcid.org/0000-0002-9483-6903"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Aaron S. Mansfield","raw_affiliation_strings":["Mayo Clinic, Rochester, Minnesota","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":"https://orcid.org/0000-0002-9483-6903","affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, Minnesota","institution_ids":["https://openalex.org/I1330342723"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005462156","display_name":"Rachel E. Sanborn","orcid":"https://orcid.org/0000-0003-0542-6054","observed_orcids":["https://orcid.org/0000-0003-0542-6054"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Rachel E. Sanborn","raw_affiliation_strings":["Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":"https://orcid.org/0000-0003-0542-6054","affiliations":[{"raw_affiliation_string":"Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon","institution_ids":["https://openalex.org/I2801670537"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036134937","display_name":"Jonathan Wade Goldman","orcid":"https://orcid.org/0000-0002-4925-8243","observed_orcids":["https://orcid.org/0000-0002-4925-8243"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I2801272649","display_name":"Ronald Reagan UCLA Medical Center","ror":"https://ror.org/04k3jt835","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801272649"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Jonathan W. Goldman","raw_affiliation_strings":["Ronald Reagan UCLA Medical Center, Los Angeles, California","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":"https://orcid.org/0000-0002-4925-8243","affiliations":[{"raw_affiliation_string":"Ronald Reagan UCLA Medical Center, Los Angeles, California","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2801272649"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089699061","display_name":"Maurice Zauderer","orcid":"https://orcid.org/0000-0002-4253-9165","observed_orcids":["https://orcid.org/0000-0002-4253-9165"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210141595","display_name":"Vaccinex (United States)","ror":"https://ror.org/047jxj944","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141595"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Maurice Zauderer","raw_affiliation_strings":["Vaccinex, Inc., Rochester, New York","affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vaccinex, Inc., Rochester, New York","institution_ids":["https://openalex.org/I4210141595"]},{"raw_affiliation_string":"affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":13,"corresponding_author_ids":["https://openalex.org/A5022624265"],"corresponding_institution_ids":["https://openalex.org/I4210141595"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/avelumab","display_name":"avelumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9139999747276306},{"id":"https://openalex.org/keywords/sema4d","display_name":"Sema4D","score":0.9860000014305115},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.7850000262260437},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.656000018119812},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7540000081062317},{"id":"https://openalex.org/keywords/cd8-t-cell-infiltration","display_name":"CD8+ T cell infiltration","score":0.7739999890327454},{"id":"https://openalex.org/keywords/pd-l1-negative-tumors","display_name":"PD-L1-negative tumors","score":0.7409999966621399},{"id":"https://openalex.org/keywords/immunotherapy-resistance","display_name":"immunotherapy resistance","score":0.7250000238418579},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7360000014305115},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6209999918937683},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.6809999942779541},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7590000033378601}],"concepts":[{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.9233158826828003},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.851919412612915},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7964634895324707},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6137616038322449},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6061248779296875},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49761679768562317},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4605082869529724},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41805967688560486},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.41175195574760437},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4049966335296631},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.40365615487098694},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.36168286204338074},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3116733431816101},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.22165673971176147}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6530526","doi":"https://doi.org/10.1158/1078-0432.c.6530526","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6530526","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6530526","doi":"https://doi.org/10.1158/1078-0432.c.6530526","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6530526","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320311647","display_name":"Merck KGaA","ror":"https://ror.org/04b2dty93"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W1699214082","https://openalex.org/W2022574491","https://openalex.org/W2031868265","https://openalex.org/W2102730296","https://openalex.org/W2114414416","https://openalex.org/W2178772862","https://openalex.org/W2186799344","https://openalex.org/W2227194925","https://openalex.org/W2471500324","https://openalex.org/W2509440460","https://openalex.org/W2599354912","https://openalex.org/W2625079306","https://openalex.org/W2808333550","https://openalex.org/W2808572932","https://openalex.org/W2890550793","https://openalex.org/W2893602866","https://openalex.org/W2900661972","https://openalex.org/W2902689957","https://openalex.org/W2903323937","https://openalex.org/W2970160545","https://openalex.org/W2975623455","https://openalex.org/W2981609323","https://openalex.org/W3000339487","https://openalex.org/W3004475955","https://openalex.org/W3020681090","https://openalex.org/W3091425478","https://openalex.org/W3115374815"],"related_works":["https://openalex.org/W3139770254","https://openalex.org/W3004737080","https://openalex.org/W2947632533","https://openalex.org/W3083467148","https://openalex.org/W3030070008","https://openalex.org/W4238194528","https://openalex.org/W3023170783","https://openalex.org/W4362418644","https://openalex.org/W4361939471","https://openalex.org/W4362411538"],"abstract_inverted_index":{"AbstractPurpose:":[0],"The":[1,91,118,231],"CLASSICAL-Lung":[2],"clinical":[3,158,211],"trial":[4],"tested":[5],"the":[6,18,24,57,142,163,175,187,195],"combination":[7,65,119,176,196,232],"of":[8,26,33,62,109,201,213,218,233,245],"pepinemab,":[9],"an":[10],"IgG4":[11],"humanized":[12],"mAb":[13],"targeting":[14],"semaphorin":[15],"4D,":[16],"with":[17,38,66,71,123,132,174,209,226,235],"PD-L1":[19],"inhibitor":[20],"avelumab":[21,67,185,236],"to":[22,55,95],"assess":[23],"effects":[25],"coupling":[27],"increased":[28,221],"T-cell":[29,40,223],"infiltration":[30],"and":[31,46,60,82,112,162,206,242,250],"reversal":[32],"immune":[34],"suppression":[35],"via":[36,42],"pepinemab":[37,63,234],"sustained":[39],"activation":[41],"checkpoint":[43],"inhibition.":[44],"Patients":[45],"Methods:":[47],"This":[48],"phase":[49,101],"Ib/II,":[50],"single-arm":[51],"study":[52],"was":[53,120,139,168,178,237],"designed":[54],"evaluate":[56,96],"safety,":[58],"tolerability,":[59],"efficacy":[61],"in":[64,68,186,198,240,248],"62":[69],"patients":[70,81,83,150,156,208],"advanced":[72],"non\u2013small":[73],"cell":[74],"lung":[75],"cancer":[76],"(NSCLC),":[77],"including":[78,203],"immunotherapy-na\u00efve":[79],"(ION)":[80],"whose":[84],"tumors":[85],"progressed":[86],"following":[87],"anti-PD-1/L1":[88],"monotherapy":[89],"(IOF).":[90],"main":[92],"objectives":[93],"were":[94],"safety/tolerability,":[97],"establish":[98],"a":[99,106,199],"recommended":[100],"2":[102,137,204],"dose":[103],"(RP2D),":[104],"obtain":[105],"preliminary":[107],"evaluation":[108],"antitumor":[110,246],"activity,":[111],"investigate":[113],"candidate":[114],"biomarker":[115],"activity.":[116],"Results:":[117],"well":[121,238],"tolerated":[122,239],"no":[124],"major":[125],"safety":[126],"signals":[127],"identified.":[128],"Pepinemab,":[129],"10":[130,134],"mg/kg":[131],"avelumab,":[133],"mg/kg,":[135],"every":[136],"weeks,":[138],"selected":[140],"as":[141],"RP2D.":[143],"Among":[144,190],"21":[145],"evaluable":[146,192],"ION":[147],"patients,":[148,194],"5":[149],"experienced":[151],"partial":[152],"responses":[153],"(PR),":[154],"4":[155],"evidenced":[157],"benefit":[159,212],"\u22651":[160],"year,":[161],"disease":[164],"control":[165],"rate":[166,173],"(DCR)":[167],"81%.":[169],"Notably,":[170],"overall":[171],"response":[172,228],"therapy":[177],"higher":[179],"than":[180],"previously":[181],"reported":[182],"for":[183],"single-agent":[184],"PD-L1-negative/low":[188,251],"population.":[189],"29":[191],"IOF":[193],"resulted":[197],"DCR":[200],"59%,":[202],"PR":[205],"7":[207],"durable":[210],"\u226523":[214],"weeks.":[215],"Biomarker":[216],"analysis":[217],"biopsies":[219],"demonstrated":[220],"CD8":[222],"density":[224],"correlating":[225],"RECIST":[227],"criteria.":[229],"Conclusions:":[230],"NSCLC":[241],"showed":[243],"signs":[244],"activity":[247],"immunotherapy-resistant":[249],"tumors.":[252]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}